AXONIS Therapeutics , Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AX
May 28, 2020
· 3 min read